Southampton

Horizontal Tabs

Overview
Our Centre 

Southampton ECMC is internationally recognised for its expertise in delivery of early phase cancer studies. The centre has a strong global reputation in the design and delivery of studies in lymphoid malignancies, urological tumours and immunotherapy. Embedded with trial delivery is a strong translational endpoint laboratory with a robust quality management system.

Our patient population

The Southampton ECMC sits at the heart of the Wessex region covering Dorset, Hampshire, Isle of Wight, South Wiltshire and the Channel Islands with a population of 3.5 million.

Jan 19-Dec 19 recruitment:

  • Recruitment to early phase studies – 72 patients
  • Recruitment to all cancer studies – 1677 patients

Organisations affiliated with the Southampton ECMC:

 

Our location

South East England

Airport: Southampton Airport

Train stations: Southampton Parkway Train Station

                        Southampton Central Train Station

Excellent motorway links to London and the rest of the UK

Contact the Centre Manager:
Debora Joseph-Pietras
d.joseph-pietras@soton.ac.uk
Address 

ECMC, WISH Lab
LF110 Level F
Mailpoint 850
Southampton General Hospital
Tremona Road
Southampton, SO16 6YD

 

Team Members
ECMC Centre Lead. Professor of Haematological Oncology. Lead for Teenagers and Young Adults
+44 (0) 238120 6186

Andrew Davies is Professor of Haematological Oncology in the Cancer Sciences Unit in the Faculty of Medicine, University Hospital Southampton. He completed his training in Medical Oncology at St Bartholomew’s Hospital in London, and as a Cancer Research UK clinical fellow he undertook a PhD examining the molecular mechanisms underlying transformation of follicular lymphoma to more aggressive histological sub-types.

Prof. Davies specialises in the treatment of malignant lymphoma and the use of high-dose chemotherapy. He has a particular interest in the investigation of monoclonal antibody-containing therapies applied to lymphoma and also in the translation of biomarkers and novel therapies to the clinical arena.  He has extensive experience in early phase trials, including leading several first in man lymphoma studies.

He is the past Chair of the UK National Cancer Research Institute High Grade Lymphoma Study Group and Director of Cancer Research UK/National Institute of Health Southampton Experimental Cancer Medicine Centre. He is also the Wessex regional lead for cancers in Teenagers and Young Adults.

 

More
Associate Professor of Medical Oncology ECMC Clinical Programme Lead. Urology Programme Lead. UHS R&D Cancer Lead
+44 (0) 238 120 5170

Associate Professor Simon Crabb is an Associate Professor in Medical Oncology at the University of Southampton, Deputy Director of Southampton Experimental Cancer Medicine Centre and Associate Clinical Director of Southampton Clinical Trials Unit. He joined the University in 2002 as a CRUK Clinical Research Fellow and completed his PhD in 2006 on novel histone deacetylase inhibitors followed by a Clinical Research Fellowship in Vancouver. Dr Crabb’s research interests include development of novel therapeutic strategies for bladder and prostate cancers, epigenetic therapeutics and mechanisms of cancer treatment resistance. He is an active clinical and translational researcher who leads a number of early phase clinical trials.

 

More
Professor of Translational Medicine. Lead Central and South Genomics Medicine Service NSHE. ECMC Translational Science Programme Lead. Genomics Lead
+44 (0) 238120 8059

Professor Tony Williams is Professor of Translational Medicine at the University of Southampton and Honorary Consultant in Clinical Immunology and Allergy.

He graduated from University College London in 1992, undertaking an intercalated degree in Pharmacology. After training in general medicine in Cardiff, he moved to Oxford for specialist training in Clinical Immunology. He was awarded a Wellcome Trust Clinician Scientist PhD Fellowship to study MHC class I presentation at the Weatherall Institute of Medicine, Oxford gaining PhD in 2003. He then moved to Southampton to complete his clinical training and was awarded a Wellcome Trust Clinician Scientist Fellowship to work on translational aspects of antigen presentation in the Cancer Sciences Division at the University of Southampton. He was appointed to a consultant post in 2003 and set up the Wessex Clinical Immunology service for Immunodeficiency disorders.

Professor Williams’ research in Primary Immunodeficiency has identified a number of novel genetic immune disorders and the Clinical Department was appointed the first International Centre of Excellence for Immunology and Allergy through the World Allergy Organisation in 2014.

Professor Williams established the Wessex Genomic Medicine centre in 2015 and co-directed the successful delivery of the 100K Genome project across Wessex. In 2019 he became the Deputy Medical Director of the West Midland, Oxford and Wessex Genomic Laboratory Hub, working to implement the advances in genomic medicine into clinical practice in cancer and rare disease.

 

More

Scientific & Operational Team

Professor of Experimental Pathology. Tumour Microenvironment Theme Lead. Pathology Lead.
+44 (0) 238 120 6184
Professor of Medical Oncology. National Clinical Director for Cancer NHSE. ECMC Lymphoid malignancies Lead
+44 (0) 238120 6186
Associate Professor in Paediatric Oncology. Paediatric Network Link and Lead for Southampton Paediatric ECMC
+44 (0) 238 120 6639
Professor of Haematology. Haematological Oncology Co-Lead
+44 (0)23 81205780
Associate Professor in Medical Oncology. Advanced therapies in solid malignancies Lead
+44 (0) 23 8120 5168
Associate Professor of Haematology. Antibody Therapeutics Lead. Haematological Oncology Co-Lead
+44 (0) 23 8120 8639
Professor of Clinical Informatics
+44 (0) 2381 207218
ECMC Translational Research Fellow and ECMC Equality, Diversity and Inclusion Lead
+44 (0) 238 120 6531
ECMC Clinical Trials Laboratory Technician
+44 (0) 238 120 8136
Quality Assurance Manager. ECMC Quality Assurance Lead. Patient and Public Engagement Lead
+44 (0) 238120 3009
CDD Biomarker Hub Laboratory Technician
+44 (0) 238 120 8136
Clinical Trials Laboratory Technician
+44 (0) 238 120 8136
CDD Biomarker Hub Laboratory Technician
+44 (0) 238 120 8136
CDD Biomarker Hub Laboratory Technician
+44 (0) 238 120 8136
Clinical Trials Laboratory Technician
+44 (0) 238 120 8136
Clinical Trials Laboratory Technician
+44 (0) 238 120 8136
Consultant Haematologist and Honorary Senior Lecturer. Advanced Therapies Lead
Expertise: 
Paediatric
Associate Professor in Head and Neck Surgery. Head and Neck Cancer Lead. Translational Immunology Lead
+44 (0) 23 8120 5745
Consultant Clinical Oncologist and Honorary Senior Lecturer. Radiotherapy/Clinical Oncology Lead
+44 (0) 23 8120 3991
Professor in Cancer Immunology Chair of the School of Cancer Sciences ED&I Committee. Equality, Diversity and Inclusion Lead. Translational Immunology Lead
+44 (0) 23 8120 5884
Professor of Clinical Trials. Trials Methodology Lead. Clinical Trials Unit Director.
+44 (0) 23 8120 5154
Professor of Cancer Genomics and Head of School of Cancer Sciences
+44 (0) 23 8120 5246
Cancer Research UK Senior Nurse and ECMC Research Nurse Lead
Clinical Trials Laboratory Technician
+44 (0) 238 120 8136

Operational Team

Senior Trials Manager. Southampton Clinical Trials Unit and ECMC Joint Project Manager
+44 (0) 23 8120 5160
Director of Research and Development UHS. R&D Lead
+44 (0) 2381 203598
Head of Clinical Trials Pharmacy Department
+44 (0) 238 120 6433
Biobank Manager
+44 (0) 238 120 5034
Research Engagement Manager. Patient and Public Involvement Lead
+44 (0) 23 8120 5723
Adult Expertise
Treatment Modalities 
Immunotherapy
Small Molecules
Facilities/Translational Research 
  • CQC registered oncology trials unit
  • Dedicated 24 hour stay faciliies (including weekends)
  • Radiopharmacy
  • On-site pharmacy
  • PK testing facility
  • Biobanking facilities 
  • Dedicated research staff
  • Snap freezing facilities 
  • On-site ITU (intensive treatment unit)
  • On-site central lab 
Cancer Types

We have expertise in both solid tumours and haematological malignancies.

Our main focus are lymphoid malignancies, urological tumours and immunotherapy. Our activity covers a whole range of early phase studies including a broad portfolio of advanced cellular therapies, development of antibody based therapies and early detection.

We host one of the four CRUK Centre for Drug Development Biomarker Centres of Excellence, with a strong translational team working on immunomonitoring and PK/PD endpoint assays.

Drug/Treatment Modalities
  • Advanced cellular therapies
  • Combination therapies
Radiotherapy
We have regular access to photon radiotherapy. We have research expertise in the following:
  • Intensity Modulated Radiotherapy (IMRT)
  • Image Guided Radiotherapy (IGRT)
  • Stereotactic Radiotherapy (SBRT/SABRT)
  • Internal Radiotherapy 
Molecular Diagnostic Testing
We have the following available on a routine basis to our patients. 
  • Single gene testing
  • Disease specific NGS panel testing (next generation sequencing)

This is available for tumour only. 

We collaborate with Oxford for ctDNA (circulating tumour DNA) in lymphoid malignancies.

 

 

Case Study
Case Studies 
Combining immunotherapies to tackle treatment resistance in lymphoma: The RiVa Trial  

This early-phase clinical trial is testing a ground breaking new method of treatment for lymphoma (cancer of the lymph glands) that could potentially change the way we treat this disease. RiVa is a trial that has been entirely conceived in Southampton, from bench to patient in just two-and-a-half years. The great majority of drugs take an average of ~12 years to enter the clinic. RiVa is looking into a new combination of two drugs to treat lymphoma – rituximab, which targets CD20-expressing cells (e.g. lymphoma cells), and varlilumab, which enhances the immune system’s anticancer activity by targeting CD27 (a marker on T cells).

This trial’s primary endpoints are safety and response rates, but it also incorporates a comprehensive translational plan. In general, it involves the collection of sequential tumour biopsies before and after treatment to allow analysis of protein markers (using multicolour flow cytometry) and gene expression (using next generation RNA sequencing). These experimental plans will be vital in helping us to determine the biomarkers that can tease out responders from non-responders. Further, in non-responders, it will also help us to elucidate the reasons for a lack of response and how we might overcome this. The majority of the analysis is being performed centrally at the Southampton ECMC, WISH Laboratory.

The trial, funded by Cancer Research UK and the Celldex Therapeutics (NJ, USA) is being managed by the Cancer Research UK Southampton Clinical Trials Unit and run in three ECMC centres in the UK: Southampton, Oxford and Manchester; as well as at Derriford Hospital, Plymouth. The trial is being conducted on patients who have relapsed or refractory lymphoma. The RiVa trial in collaboration with the School of Cancer Sciences, Centre of Cancer Immunology, ECMC WISH Lab, Faculty of Medicine and sponsored by University Hospital Southampton NHS Foundation Trust.

“In this small trial, some people responded to the combination treatment and some did not, as one would expect from any study,” says Dr Lim, Antibody & Vaccine Group, Centre for Cancer Immunology, Southampton.

“But what is really interesting is that we have found clues as to what the varlilumab is doing in the tumours, helping us to better understand why there is a response in some patients and not in others.”

Varlilumab is a CD27 agonist. This means it binds to the CD27 receptor on T cells and stimulates a pathway that leads to more T cells being produced and the release of chemicals which activate another type of immune cell called macrophages. These macrophages are able to destroy the cancerous B cells that have been marked by the rituximab.

“With RiVa, we took needle biopsies of the tumours from patients who only had rituximab versus those who had the combination of rituximab and varlilumab,” continues Dr Lim.

“What we saw in those who also had varlilumab was an increase in activated T cells and evidence of activated macrophages. This data gives us confidence that varlilumab is stimulating the immune system.”

“But when we looked at the patients who responded to the combination treatment, versus those who did not, we found that the responders had a greater increase in the number of T cells, and a ‘hotter’ immune environment, so more expression of the genes that lead to an immune response.”

“This suggests that the patients who are going to respond to T cell stimulation are probably the ones with a more active immune environment. We don’t have a means to pick these people out yet, but we are another step along the way.”

“Our next steps are to look for a better agonist. We see that varlilumab is stimulating the immune pathways, but it’s a weak agonist. My lab is now looking at how we can engineer antibodies to optimally. We are also looking at other immune-stimulatory antibodies, beyond CD27.”

Southampton ECMC has in-house expertise in the design and conduct of early phase clinical trials with immunomodulatory compounds